Houston, TX’ - In a significant move to advance cancer therapy, Kiromic BioPharma, Inc. (OTCQB: KRBP) has announced the activation of the University of Arizona Cancer Center (UACC) as the fifth clinical trial site for the ongoing Phase 1 Deltacel-01 trial. This trial focuses on the evaluation of Deltacel (KB-GDT-01), an allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy. This innovative treatment is being tested for its effectiveness in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have not responded to standard therapies.
The UACC is among the elite 57 NCI-designated Comprehensive Cancer Centers in the United States, a tribute to its excellence in cancer research, treatment, and education. The activation of UACC as a trial site is seen as a strategic move to leverage the center’s advanced research capabilities and comprehensive patient care services to further the development of Deltacel.
The Phase 1 Deltacel-01 Trial: A Glimmer of Hope’
The Deltacel-01 Phase 1 trial is designed to evaluate the safety, tolerability, and preliminary efficacy of Kiromic’s proprietary Gamma Delta T-cell therapy in a patient population that is in dire need of advanced treatment options. NSCLC is known for its poor prognosis, especially in its metastatic form, and current treatment regimens often fall short, leaving patients with limited alternatives.
Deltacel represents a beacon of hope in this landscape. Unlike traditional autologous approaches that require harvesting and modifying a patient’s own cells, Kiromic’s allogeneic therapy uses T-cells derived from healthy donors. These cells are then genetically engineered to enhance their cancer-fighting abilities, creating a potentially more efficient and accessible treatment option.
The Role of UACC in this Pioneering Research’
The University of Arizona Cancer Center’s inclusion in the Deltacel-01 trial is expected to bring multiple benefits. First, it ensures a broader patient base, enhancing the statistical power and robustness of the trial’s findings. Second, it leverages UACC’s state-of-the-art facilities and experienced research team, which can provide invaluable insights and data.
Dr. X, a leading oncologist and researcher at UACC, expressed optimism about the collaboration. We are excited to join forces with Kiromic BioPharma in this groundbreaking trial. Our shared goal is to bring innovative treatments to patients who desperately need them. The preliminary data for Deltacel is promising, and we are eager to contribute to its potential success.
Expanding the Horizons of Cancer Treatment’
Kiromic BioPharma’s decision to expand the Deltacel-01 trial to UACC aligns with its broader strategy to establish a robust pipeline of advanced immunotherapies. The company’s focus on Gamma Delta T-cell technology is based on the unique properties of these cells, which are known for their potent anti-tumor activity and ability to target multiple types of cancer cells without harming normal cells.
We are thrilled to welcome the University of Arizona Cancer Center as our fifth clinical trial site, said Mr. Y, CEO of Kiromic BioPharma. This collaboration underscores our commitment to advancing our allogeneic Gamma Delta T-cell therapy platform and ultimately improving outcomes for patients with metastatic NSCLC.
The Path Forward’
As the Deltacel-01 trial progresses, Kiromic BioPharma remains dedicated to rigorous scientific inquiry and patient safety. The addition of UACC as a trial site is a testament to the trial’s growing momentum and the high level of interest in Deltacel as a potential game-changer in cancer therapy.
The coming months promise to be crucial as more data becomes available, potentially paving the way for subsequent trial phases and a broader application of this innovative therapy. Both Kiromic BioPharma and the University of Arizona Cancer Center are committed to ensuring the highest standards of clinical research as they work together to bring new hope to patients battling metastatic NSCLC.
Comments